Skip to main content
  • Register
  • Help
  • Contact us
  • Log out of your HL account

Progenics Pharmaceuticals Inc (PGNX) Com Stk USD0.0013

Sell:$4.81 Buy:$4.82 Change: $0.24 (4.75%)
NASDAQ:0.19%
Market closed |  Prices as at close on 23 October 2019 | Switch to live prices |
Sell:$4.81
Buy:$4.82
Change: $0.24 (4.75%)
Market closed |  Prices as at close on 23 October 2019 | Switch to live prices |
Sell:$4.81
Buy:$4.82
Change: $0.24 (4.75%)
Market closed |  Prices as at close on 23 October 2019 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Progenics Pharmaceuticals, Inc. is engaged in developing medicines and other products for targeting and treating cancer. The Company's pipeline includes therapeutic agents designed to target cancer (AZEDRA and 1095); prostate specific membrane antigen (PSMA)-targeted imaging agents for prostate cancer (1404 and PyL), and imaging analysis tools. It also includes commercial product, RELISTOR (methylnaltrexone bromide) for opioid-induced constipation. AZEDRA is a radiotherapeutic product candidate in development as a treatment for malignant and/or recurrent pheochromocytoma and paraganglioma, rare tumors found in the adrenal glands and outside of the adrenal glands, respectively. RELISTOR is a treatment for opioid induced constipation. PyL is a clinical-stage, fluorinated PSMA-targeted Positron Emission Topography (PET) imaging agent for prostate cancer. PSMA TTC is a thorium-227 labeled PSMA-targeted antibody therapeutic.

Contact details

Address:
1 World Trade Ctr Fl 47
NEW YORK
10007-0089
United States
Telephone:
+1 (646) 9752500
Website:
www.progenics.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
PGNX
ISIN:
US7431871067
Market cap:
$437.44 million
Shares in issue:
86.62 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
NASDAQ Comb. Composite

Key personnel

  • Mark Baker
    Chief Executive Officer, Director
  • Patrick Fabbio
    Chief Financial Officer, Senior Vice President
  • Benedict Osorio
    Chief Operating Officer
  • Vivien Wong
    Executive Vice President - Development
  • Bryce Tenbarge
    Senior Vice President - Commercial
  • Huw Jones
    Vice President - Commercial
  • Asha Das
    Chief Medical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.